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Gene expressionInterstitial cystitis and bladder pain syndrome (IC/BPS) are termsused to describe a heterogeneous chronic pelvic
and bladder pain disorder. Despite its signiﬁcant prevalence, the disease etiology is not well understood and pro-
viding diagnosis and treatment can be challenging. In our study, published recently in the Journal of Urology
(Colaco et al., 2014), we describe the use of microarrays as a tool to characterize IC/BPS and to determine if
there are clinical factors that correlate with gene expression. This data-in-brief article describes themethodology
for that study, including data analysis, in further detail. Deposited data can be found in the Gene Expression
Omnibus (GEO) database: GSE57560.
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c. This is an open access article undeSpeciﬁcationsOrganism/cell
line/tissueHomo sapiensGender Female
Strain(s) Patient bladder biopsy tissue
Sequencer or
array typeSurePrint Human Gene Expression v2 microarrays (Agilent)Data format Raw data, extracted from scanned images using Agilent
Feature Extraction SoftwareExperimental
factorsLow bladder capacity versus normal capacity and controlConsent All patients gave written informed consent for this study.Deposited data can be found in the Gene Expression Omnibus
(GEO) database: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE57560. GSE57560 — Correlation of gene expression with bladder
capacity in interstitial cystitis/bladder pain syndrome.
Experimental design, materials and methods
Sample procurement
A ﬂow diagram outlining of the experimental design for this study
can be found in Fig. 1. Experimental biopsy tissue was collected eitherduring cystoscopy or at surgery (for patients who were undergoing
cystectomy for end stage disease) under general anesthesia from
patients diagnosed with interstitial cystitis/bladder pain syndrome
(IC/BPS) [1–5]. Cystoscopy patients ﬁrst underwent hydrodistention at
100 mL of H2O for a period of 5 min. Study biopsies were taken post
hydrodistention from the posterior bladder wall using a cold-cup tech-
nique and a portion of each biopsy specimen was sent for normal clini-
cal analysis by the Wake Forest Medical Center pathology department
(following standard hospital protocol). The remaining sample was
immediately submerged in 200 μL of RNAlater® and stored at−20 °C
until processing. For patients undergoing cystectomy, an amount of
tissue similar to that which would be collected at biopsy was harvested
from the posterior bladder through a single scalpel incision and sub-
merged in 200 μL of RNAlater® and stored at −20 °C in a similar
fashion. Bladder capacity data and cystoscopic ﬁndings for these sub-
jects were retrieved from the patient's last cystoscopy recording in the
medical record and included in this analysis (Table 1). For the purposes
of this study, low bladder capacity was deﬁned as b400 mL (volume at
hydrodistention) [6].
Control tissue was likewise collected during cystoscopy. As these
patients did not have any clinical indication for the performance of
hydrodistention, this procedure was not done (Table 1).RNA extraction and QC
Biopsy tissue was homogenized by sonication and total RNA was
extracted using RNeasy Minelute Plus columns (includes on-column
DNase digestion) and reagents (Qiagen, Valencia, CA) according to ther the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Flow diagram representing the outline of experimental steps. Brieﬂy, total RNA,
isolated from bladder biopsies procured in the clinic, was reversed transcribed, labeled,
and hybridized to whole genome microarrays. The arrays were then scanned and the
data were analyzed for differential gene expression between disease and control groups.
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nuclease-freewater and RNA quantity and purity was determined spec-
trophotometrically on a Nanodrop ND-1000 (Nanodrop Technologies,
Wilmington, DE) by measuring absorbance at 260/280 nm (mean for
all samples = 2.09 ± 0.02) and RNA quality was determined using anAgilent Bioanalyzer (Agilent Technologies, Inc., Palo Alto, CA; mean
RIN = 9.4 ± 0.24 for all samples). Total RNA was shipped on dry ice
to a microarray core facility (City of Hope Functional Genomics Core,
Duarte, CA) for processing.Gene expression analysis by microarray
Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 μg total RNA
using the One-Color Low RNA Input Linear Ampliﬁcation PLUS kit
(Agilent) according to the manufacturer's instructions, followed by
RNAeasy column puriﬁcation (QIAGEN, Valencia, CA). Dye incorpora-
tion and cRNA yield were checked with the NanoDrop ND-1000
Spectrophotometer. 1.5 μg of Cy3-labeled cRNA (speciﬁc activity
N10.0 pmol Cy3/μg cRNA) was fragmented at 60 °C for 30 min in
a reaction volume of 250 mL containing 1× Agilent fragmentation
buffer and 2× Agilent blocking agent following the manufacturer 's
instructions. On completion of the fragmentation reaction, 250 mL
of 2× Agilent hybridization buffer was added to the fragmentation
mixture and hybridized to SurePrint Human Gene Expression v2micro-
arrays (Agilent Technologies) containing 60-mers for 50,599 biological
features for 17 h at 65 °C in a rotating Agilent hybridization oven.
After hybridization, microarrays were washed 1 min at room tem-
perature with GE Wash Buffer 1 (Agilent) and 1 min with 37 °C GE
Wash buffer 2 (Agilent), then dried immediately by brief centrifuga-
tion. Slides were scanned immediately after washing on the Agilent
DNA Microarray Scanner (G2505B) using one color scan setting for
1 × 44 k array slides (Scan Area 61 × 21.6 mm, Scan resolution
10 μm, Dye channel is set to Green and Green PMT is set to 100%).
The scanned images were analyzed with Feature Extraction Software
9.1 (Agilent) using default parameters (protocol GE1-v1_91 and
Grid: 012391_D_20060331) to obtain background subtracted and
spatially de-trended Processed Signal intensities. Features ﬂagged
in Feature Extraction as Feature Non-uniform outliers were excluded.
The anonymized clinical data were deposited in the Gene Expression
Omnibus database (GEO http://www.ncbi.nlm.nih.gov/geo/ under
accession number GSE57560).Data processing for gene expression and gene ontology/pathway analysis
Following log transformation of the Processed Signal intensity data,
principle component analysis (PCA) and unsupervised hierarchical
clustering were performed (Qlucore Omics Explorer) to determine the
similarity among samples within and between groups (Fig. 2). Further
statistical analyses to measure differentially expressed transcripts
(DETs) unique to each phenotype were then performed by applying
Student's t-test (@fold change≥1.5; p≤ 0.05) for the pair-wise compar-
ison (GeneSifter© Analysis Edition 4.0) using Benjamini and Hochberg
FDR correction [7]. The list of DETs generated from the pair-wise com-
parison (e.g. low bladder capacity versus normal bladder capacity) with
an adjusted p ≤ 0.05 was imported into Ingenuity Pathway Analysis
software for gene ontology and pathway analysis.Discussion
Gene expression analysis provides insight into the pathobiology
underlying IC/BPS. We demonstrate that low capacity and normal
capacity IC/BPS bladders have signiﬁcantly different molecular charac-
teristics, and this difference may reﬂect a fundamental difference in
disease processes. Meanwhile, IC/BPS patients with normal bladder
capacity exhibit similar molecular proﬁles to control subjects [7]. Given
the promising results of this pilot study we are conducting further
research into the correlation between molecular and clinical ﬁndings
and the development of an IC/BPS biomarker.
Fig. 2. Gene expression in IC cases and controls. Hierarchical clustering, based on bladder capacity, was performed on whole genome microarray data. For the principle components
analysis (PCA; Panel A) the signiﬁcance threshold was set at p ≤ 0.05. Each colored circle on the plot represents the cumulative expression of 4363 transcripts for that sample (Panel A).
The heatmap displays the top 48 differentially expressed genes based on bladder capacity (Panel B). Panels A & B: violet = low capacity; yellow = normal capacity; blue = controls.
Table 1
Clinical data and demographic information for cases and controls. Demographic and clinical data for each of the 16 subjects. Subject #11 had biopsy performed during cystoscopy then
underwent cystectomy at a later date.
Subject Age Capacity O'Leary-Sant PUF Glomerulations Ulceration Cystectomy
Normal capacity
1 47 900 30 26 Mild No No
2 27 1400 30 25 Mild No No
3 57 1350 16 17 Moderate No No
4 32 900 26 26 Moderate No No
5 37 1000 28 30 Severe No No
6 25 900 31 27 Severe No No
7 24 1200 19 22 Severe No No
8 23 600 33 27 Severe No Yes
9 63 400 23 15 Mild No No
Low capacity
10 57 300 32 26 Severe No No
11 46 225 35 30 Moderate No Yes
12 67 175 35 33 Severe Yes Yes
13 65 275 25 17 Mild Yes Yes
Control
14 76 Not reported Not reported Not reported NA No No
15 43 1600 14 14 NA No No
16 53 850 25 25 NA No No
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